Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection

A 79-year-old woman presented with a week-long history of shortness of breath. She had a background of idiopathic pulmonary fibrosis (IPF) which was stable and had not required any antifibrotic treatment. A month prior to this presentation, she was admitted with COVID-19 pneumonia, with maximal oxygen requirement of 2 L, but was discharged without need for supplemental oxygen. On readmission, she was found to have severe, rapidly progressive pulmonary fibrosis. After all precipitating causes were ruled out, it was felt her recent COVID-19 infection was the exacerbating factor causing progression of pulmonary fibrosis. COVID-19 infection has been hypothesised to cause long term pulmonary fibrosis, but this is the first case highlighting COVID-19 infection as the causative agent exacerbating IPF.

Download Full-text

Long-Term Combined Training in Idiopathic Pulmonary Fibrosis: A Case Study

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph17145091 ◽

2020 ◽

Vol 17 (14) ◽

pp. 5091

Author(s):

José Naranjo-Orellana ◽

Alfredo Santalla

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Lung Transplantation ◽

Interval Training ◽

Load Resistance ◽

Supplemental Oxygen ◽

Peak Oxygen Uptake ◽

Combined Training ◽

Walking Capacity

A supervised combined training program was applied to a sedentary 56-year-old man with idiopathic pulmonary fibrosis (IPF) along three years, until lung transplantation. It included: (a) aerobic continuous (CT) and interval training (IT), (b) high load resistance training (RT) and (c) inspiratory muscle training (IMT). IT and IMT were applied for two years, while CT and RT could be maintained until transplantation using supplemental oxygen. Maximal inspiratory pressure (MIP) kept above 180 cm H2O and forced vital capacity (FVC) remained stable until lung transplantation. Peak oxygen uptake VO2 increased during 1.5 years before its decline, staying above the poor prognosis level two years. Finally, the patient maintained his walking capacity and independence for 2 years, before the decline due to the disease. After receiving a two-lung transplant, the patient remained intubated for 12 h, left the intensive care unit after 3.5 days and was discharged after 18 days (average values: 48 h, 7–10 days and 25–35 days, respectively). These results show that systematic and supervised combined training can be safety applied in an IPF patient to maintain functionality and quality of life. In addition, we show that RT can be maintained for as long as necessary without complications.

Download Full-text

Fungki Ulcers

Archives of Medical Case Reports and Case Study ◽

10.31579/2692-9392/012 ◽

2020 ◽

Vol 3 (1) ◽

pp. 01-03

Author(s):

Shaadi Abughazaleh

Keyword(s):

Deep Vein Thrombosis ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Shortness Of Breath ◽

Vein Thrombosis ◽

Bilateral Lung Transplantation ◽

Immunosuppressive Medications ◽

History Of ◽

Bilateral Lung ◽

Deep Vein

A 61-year-old female with a history of bilateral lung transplantation for idiopathic pulmonary fibrosis presented with shortness of breath, cough and diarrhea. She was on chronic immunosuppressive medications, including Tacrolimus and mycophenolate, and on apixaban for deep vein thrombosis.

Download Full-text

Mean Nocturnal Baseline Impedance Measured on Impedanceph Monitoring Predicts Supplemental Oxygen Requirement Increase after 1 Year in Patients with Idiopathic Pulmonary Fibrosis

Gastroenterology ◽

10.1016/s0016-5085(17)32320-x ◽

2017 ◽

Vol 152 (5) ◽

pp. S659

Author(s):

Kelly Hathorn ◽

Lawrence F. Borges ◽

Sravanya Gavini ◽

Wai-Kit Lo ◽

Robert Burakoff ◽

...

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Supplemental Oxygen ◽

Oxygen Requirement

Download Full-text

Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON

10.1055/s-0039-1678102 ◽

2019 ◽

Author(s):

U Costabel ◽

B Crestani ◽

M Quaresma ◽

M Kaye ◽

T Ogura ◽

...

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Final Data

Download Full-text

S19 The impact of clotting abnormalities on the natural history of idiopathic pulmonary fibrosis: an extended follow up of a population based cohort

Thorax ◽

10.1136/thoraxjnl-2016-209333.25 ◽

2016 ◽

Vol 71 (Suppl 3) ◽

pp. A13.1-A13

Author(s):

V Navaratnam ◽

AW Fogarty ◽

T McKeever ◽

N Thompson ◽

G Jenkins ◽

...

Keyword(s):

Natural History ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Population Based ◽

History Of ◽

The Impact

Download Full-text

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

Thorax ◽

10.1136/thoraxjnl-2016-209701 ◽

2017 ◽

Vol 73 (6) ◽

pp. 581-583 ◽

Cited By ~ 21

Author(s):

Luca Richeldi ◽

Michael Kreuter ◽

Moisés Selman ◽

Bruno Crestani ◽

Anne-Marie Kirsten ◽

...

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Term Treatment ◽

Adverse Event Profile ◽

Open Label ◽

Comparator Group ◽

Long Term Treatment ◽

Open Label Extension ◽

Rate Of Decline

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.

Download Full-text